Clinical Trials
8 trialsNCT07300475 2026-05-07
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07528768 2026-04-14
Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer
AntiCancer Research Jamaica
Phase 2 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07187674 2025-09-23
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Harbin Medical University
Phase NA Not yet recruiting
NCT06795503 2025-01-28
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
Fudan University
Phase 3 Not yet recruiting
NCT06407310 2024-05-09
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
Tel Aviv Medical Center
Phase 2 Not yet recruiting
NCT06371807 2024-04-17
KEYPARTNER
Fundacao Champalimaud
Phase 2 Not yet recruiting
NCT05067530 2021-10-05
CAREGIVER
Medical University of Gdansk
Phase 2 Not yet recruiting